Biomarkers Market by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021

The global biomarkers market is estimated to reach USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, at a CAGR of 13.8% from 2016 to 2021.

The global market is segmented on the basis of product, type, application, disease indication, and region.

On the basis of product, the Market is segmented into consumables, services, and software. The consumables segment is estimated to account for the largest share of the global market in 2016. The large share of this segment is primarily attributed to the lower price of consumables than that of screening and automation instruments.

On the basis of type, the Market is segmented into safety, efficacy, and validation. The efficacy segment is further classified into predictive, surrogate, pharmacodynamic, and prognostic. In 2016, the safety segment is expected to account for the largest share of the market. However, the efficacy biomarkers segment is estimated to register the highest CAGR during the forecast period.

On the basis of application, the global Market is categorized into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications (DNA fingerprinting, ecotoxicology, and forensics). The diagnostics segment is estimated to account for the largest share of the market in 2016. Factors such as increasing prevalence of cancer, increased awareness and acceptance of diagnostic tests, technologically developed biomarker products, and individualized treatments for cancer are driving the growth of this segment.

On the basis of disease indication, the market is categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others (renal disorders, urinal diseases, diabetes, and tuberculosis). The cancer segment is estimated to account for the largest share of the global market in 2016. Cancer forms the largest segment primarily due to the increasing prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.

Growth in the Market is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market.

The biomarkers market is dominated by established players such as QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Enzo Biochem, Inc. (U.S.).

Stakeholders

• Academic Research Institutes
• Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
• Contract Research Organizations (CROs)
• Diagnostics Companies
• Market Research and Consulting Firms
• Pharmaceutical Companies
• Regulators
• Payers

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report

• The market study doesn’t cover the market size in terms of volume
• Some companies in this market are privately owned and their revenues are not available in the public domain. Hence, revenue for those companies are not included in this report
• Company developments not reported in the public domain are not included in this report

Biomarkers Market Segmentation

This research report categorizes the biomarkers market on the basis of product, type, application, disease indication, and region

• Consumables
• Services
• Software

Biomarkers Market, by Type

• Safety Biomarkers
• Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamic Biomarkers
  • Prognostic Biomarkers
• Validation Biomarkers

By Application

• Diagnostics Development
• Drug Discovery and Development
• Personalized Medicine
• Disease Risk Assessment
• Other Applications (DNA Fingerprinting, Ecotoxicology, and Forensics)

By Disease Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Immunological Disorders
• Others (Renal Disorders, Urinal Diseases, Diabetes, and Tuberculosis)

By Region

• North America
  • U.S.
  • Canada
• Europe
• Asia
  • China
  • Japan
  • Rest of Asia
• Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

• Country-wise analysis of the European biomarkers market

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

Browse Related Report: Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022

https://www.marketsandmarkets.com/Market-Reports/biomarker-technologies-market-190358765.html

Table of Contents

1 Introduction (Page No. - 13)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered in the Report
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 17)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
           2.2.1 Key Data From Secondary Sources
           2.2.2 Key Data From Primary Sources
    2.3 Market Rank Estimation
    2.4 Key Industry Insights
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 25)

4 Premium Insights (Page No. - 29)
    4.1 Market Overview
    4.2 By Product (2016)
    4.3 By Type, 2016 vs 2021
    4.4 By Application, 2016 vs 2021
    4.5 By Disease Indication, 2016 vs 2021
    4.6 Geographic Growth Opportunities
    4.7 Life Cycle Analysis, By Region, 2016

5 Biomarkers Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Biomarkers Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Diagnostic Applications of Biomarkers
                               5.2.1.1.1 Personalized Medicine
                               5.2.1.1.2 Companion Diagnostics
                    5.2.1.2 Increasing R&D Funding for Pharma and Biotech Companies
                    5.2.1.3 Increasing Number of Cros and Low Cost of Clinical Trials in Developing Countries
                    5.2.1.4 High Prevalence of Cancer
                    5.2.1.5 New Initiatives for Biomarker Research
           5.2.2 Restraints
                    5.2.2.1 High Capital Investments and Low Cost-Benefit Ratio
                    5.2.2.2 Poorly Suited Regulatory and Reimbursement Systems
                    5.2.2.3 Technical Issues Related to Sample Collection and Storage
           5.2.3 Opportunities
                    5.2.3.1 Emerging Economies
           5.2.4 Challenges
                    5.2.4.1 Proving the Clinical Validity in Biomarker-Based Tests

6 Biomarkers Market, By Product (Page No. - 43)
    6.1 Introduction
    6.2 Consumables
    6.3 Services
    6.4 Software

7 By Type (Page No. - 50)
    7.1 Introduction
    7.2 Safety Biomarkers
    7.3 Efficacy Biomarkers
           7.3.1 Predictive Biomarkers
           7.3.2 Surrogate Biomarkers
           7.3.3 Pharmacodynamic Biomarkers
           7.3.4 Prognostic Biomarkers
    7.4 Validation Biomarkers

8 By Application (Page No. - 63)
    8.1 Introduction
    8.2 Diagnostics
    8.3 Drug Discovery and Development
    8.4 Personalized Medicine
    8.5 Disease Risk Assessment
    8.6 Other Applications

9 By Disease Indication (Page No. - 76)
    9.1 Introduction
    9.2 Cancer
    9.3 Cardiovascular Disorders
    9.4 Neurological Disorders
    9.5 Immunological Disorders
    9.6 Other Diseases

10 By Region (Page No. - 89)
     10.1 Introduction
     10.2 North America
             10.2.1 U.S.
             10.2.2 Canada
     10.3 Europe
     10.4 Asia
             10.4.1 China
             10.4.2 Japan
             10.4.3 Rest of Asia
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 118)
     11.1 Overview
     11.2 Competitive Situation and Trends
             11.2.1 Product Launches
             11.2.2 Collaborations, Partnerships, and Agreements
             11.2.3 Acquisitions
             11.2.4 Other Developments
     11.3 Leading Players in the Global Market

12 Company Profiles (Page No. - 124)
(Overview, Products and Services, Financials, Strategy & Development)*
     12.1 Qiagen N.V.
     12.2 Perkinelmer, Inc.
     12.3 Merck Millipore
     12.4 Bio-Rad Laboratories, Inc.
     12.5 Enzo Biochem, Inc.
     12.6 EKF Diagnostics Holdings, Inc.
     12.7 Meso Scale Diagnostics, LLC.
     12.8 Biosims Technologies Sas
     12.9 Cisbio Bioassays
     12.10 Signosis, Inc.

*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 146)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Other Developments
     13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.5 Introducing RT: Real-Time Market Intelligence
     13.6 Available Customizations
     13.7 Related Reports
     13.8 Author Details

List of Tables (117 Tables)

Table 1 List of Fda-Approved Biomarkers for Different Types of Cancer
Table 2 Market Size, By Product, 2014–2021 (USD Billion)
Table 3 Biomarkers Consumables Market Size, By Region, 2014–2021 (USD Billion)
Table 4 North America: Biomarkers Consumables Market Size, By Country, 2014–2021 (USD Billion)
Table 5 Asia: Biomarkers Consumables Market Size, By Country, 2014–2021 (USD Billion)
Table 6 Biomarkers Services Market Size, By Region, 2014–2021 (USD Billion)
Table 7 North America: Biomarkers Services Market Size, By Country, 2014–2021 (USD Billion)
Table 8 Asia: Biomarkers Services Market Size, By Country, 2014–2021 (USD Billion)
Table 9 Biomarkers Software Market Size, By Region, 2014–2021 (USD Billion)
Table 10 North America: Biomarkers Software Market Size, By Country, 2014–2021 (USD Billion)
Table 11 Asia: Biomarkers Software Market Size, By Country, 2014–2021 (USD Billion)
Table 12 Market Size, By Type, 2014–2021 (USD Billion)
Table 13 Safety Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 14 North America: Safety Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 15 Asia: Safety Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 16 Efficacy Biomarkers Market Size, By Type, 2014–2021 (USD Billion)
Table 17 Efficacy Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 18 North America: Efficacy Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 19 Asia: Efficacy Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 20 Predictive Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 21 North America: Predictive Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 22 Surrogate Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 23 North America: Surrogate Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 24 Pharmacodynamic Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 25 North America: Pharmacodynamic Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 26 Prognostic Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 27 North America: Prognostic Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 28 Validation Biomarkers Market Size, By Region, 2014–2021 (USD Billion)
Table 29 North America: Validation Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 30 Asia: Validation Biomarkers Market Size, By Country, 2014–2021 (USD Billion)
Table 31 Market Size, By Application, 2014–2021 (USD Billion)
Table 32 Market Size for Diagnostics Development, By Region, 2014–2021 (USD Billion)
Table 33 North America: Market Size for Diagnostics Development, By Country, 2014–2021 (USD Billion)
Table 34 Asia: Market Size for Diagnostics Development, By Country, 2014–2021 (USD Billion)
Table 35 Market Size for Drug Discovery and Development, By Region, 2014–2021 (USD Billion)
Table 36 North America: Market Size for Drug Discovery and Development, By Country, 2014–2021 (USD Billion)
Table 37 Asia: Market Size for Drug Discovery and Development, By Country, 2014–2021 (USD Billion)
Table 38 Market Size for Personalized Medicine, By Region, 2014–2021 (USD Billion)
Table 39 North America: Market Size for Personalized Medicine, By Country, 2014–2021 (USD Billion)
Table 40 Asia: Market Size for Personalized Medicine, By Country, 2014–2021 (USD Billion)
Table 41 Market Size for Disease Risk Assessment, By Region, 2014–2021 (USD Billion)
Table 42 North America: Market Size for Disease Risk Assessment, By Country, 2014–2021 (USD Billion)
Table 43 Asia: Market Size for Disease Risk Assessment, By Country, 2014–2021 (USD Billion)
Table 44 Market Size for Other Applications, By Region, 2014–2021 (USD Billion)
Table 45 North America: Market Size for Other Applications, By Country, 2014–2021 (USD Billion)
Table 46 Asia: Market Size for Other Applications, By Country, 2014–2021 (USD Million)
Table 47 Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 48 Key Cancer Biomarkers in Clinical Use
Table 49 Market Size for Cancer, By Region, 2014–2021 (USD Billion)
Table 50 North America: Market Size for Cancer, By Country, 2014–2021 (USD Billion)
Table 51 Asia: Market Size for Cancer, By Country, 2014–2021 (USD Billion)
Table 52 Biomarkers for Cardiovascular Disorder
Table 53 Market Size for Cardiovascular Disorders, By Region, 2014–2021 (USD Billion)
Table 54 North America: Market Size for Cardiovascular Disorders, By Country, 2014–2021 (USD Billion)
Table 55 Asia: Market Size for Cardiovascular Disorders, By Region/Country, 2014–2021 (USD Billion)
Table 56 Market Size for Neurological Disorders, By Region, 2014–2021 (USD Billion)
Table 57 North America: Market Size for Neurological Disorders, By Country, 2014–2021 (USD Billion)
Table 58 Asia: Market Size for Neurological Disorders, By Region/Country, 2014–2021 (USD Billion)
Table 59 Biomarkers for Immunological Disorders
Table 60 Market Size for Immunological Disorders, By Region, 2014–2021 (USD Billion)
Table 61 North America: Market Size for Immunological Disorders, By Country, 2014–2021 (USD Billion)
Table 62 Asia: Market Size for Immunological Disorders, By Region/Country, 2014–2021 (USD Billion)
Table 63 Biomarkers for Renal Disorders
Table 64 Market Size for Other Diseases, By Region, 2014–2021 (USD Billion)
Table 65 North America: Market Size for Other Diseases, By Country, 2014–2021 (USD Billion)
Table 66 Asia: Market Size for Other Diseases, By Country, 2014–2021 (USD Billion)
Table 67 Market Size, By Region, 2014–2021 (USD Billion)
Table 68 North America: Market Size, By Country, 2014–2021 (USD Billion)
Table 69 North America: Market Size, By Product, 2014–2021 (USD Billion)
Table 70 North America: Market Size, By Type, 2014–2021 (USD Billion)
Table 71 North America: Efficacy Market Size, By Type, 2014–2021 (USD Billion)
Table 72 North America: Market Size, By Application, 2014–2021 (USD Billion)
Table 73 North America: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 74 U.S.: Market Size, By Product, 2014–2021 (USD Billion)
Table 75 U.S.: Market Size, By Type, 2014–2021 (USD Billion)
Table 76 U.S.: Efficacy Market Size, By Type, 2014–2021 (USD Billion)
Table 77 U.S.: Market Size, By Application, 2014–2021 (USD Billion)
Table 78 U.S.: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 79 Canada: Market Size, By Product, 2014–2021 (USD Billion)
Table 80 Canada: Market Size, By Type, 2014–2021 (USD Billion)
Table 81 Canada: Efficacy Market Size, By Type, 2014–2021 (USD Billion)
Table 82 Canada: Market Size, By Application, 2014–2021 (USD Billion)
Table 83 Canada: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 84 Europe: Market Size, By Product, 2014–2021 (USD Billion)
Table 85 Europe: Market Size, By Type, 2014–2021 (USD Billion)
Table 86 Europe: Efficacy Biomarkers Market Size, By Type, 2014–2021 (USD Billion)
Table 87 Europe: Market Size, By Application, 2014–2021 (USD Billion)
Table 88 Europe: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 89 Asia: Market Size, By Country, 2014–2021 (USD Billion)
Table 90 Asia: Market Size, By Product, 2014–2021 (USD Billion)
Table 91 Asia: Market Size, By Type, 2014–2021 (USD Billion)
Table 92 Asia: Efficacy Biomarkers Market Size, By Type, 2014–2021 (USD Billion)
Table 93 Asia: Market Size, By Application, 2014–2021 (USD Billion)
Table 94 Asia: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 95 China: Market Size, By Product, 2014–2021 (USD Billion)
Table 96 China: Market Size, By Type, 2014–2021 (USD Billion)
Table 97 China: Market Size, By Application, 2014–2021 (USD Billion)
Table 98 China: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 99 Japan: Market Size, By Product, 2014–2021 (USD Billion)
Table 100 Japan: Market Size, By Type, 2014–2021 (USD Billion)
Table 101 Japan: Market Size, By Application, 2014–2021 (USD Billion)
Table 102 Japan: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 103 Rest of Asia: Market Size, By Product, 2014–2021 (USD Billion)
Table 104 Rest of Asia: Market Size, By Type, 2014–2021 (USD Billion)
Table 105 Rest of Asia: Market Size, By Application, 2014–2021 (USD Billion)
Table 106 Rest of Asia: Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 107 RoW: Market Size, By Product, 2014–2021 (USD Billion)
Table 108 RoW: Market Size, By Type, 2014–2021 (USD Billion)
Table 109 RoW: Efficacy Biomarkers Market Size, By Type, 2014–2021 (USD Billion)
Table 110 RoW: Market Size, By Application, 2014–2021 (USD Billion)
Table 111 RoW: Biomarkers Market Size, By Disease Indication, 2014–2021 (USD Billion)
Table 112 Battle for Market Share: Product Launch Was the Key Strategy Adopted By Market Players in Biomarkers Market Between 2014 and 2016
Table 113 Product Launches, 2014–2016
Table 114 Collaborations, Partnerships, and Agreements, 2014–2016
Table 115 Acquisitions, 2014–2016
Table 116 Other Developments, 2014–2016
Table 117 Rank of Companies in the Biomarkers Market, 2016

List of Figures (37 Figures)

Figure 1 Biomarkers Market Segmentation
Figure 2 Research Design
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Market Size, By Product, 2016 vs 2021 (USD Billion)
Figure 8 Market Size, By Type, 2016 vs 2021 (USD Billion)
Figure 9 Market Size, By Application, 2016 vs 2021 (USD Billion)
Figure 10 Market Size, By Disease Indication, 2016 vs 2021 (USD Billion)
Figure 11 Market Size, By Region, 2016 vs 2021 (USD Billion)
Figure 12 Market to Register A High, Double-Digit Growth Rate During the Forecast Period
Figure 13 Consumables Segment to Account for the Largest Market Share in 2016
Figure 14 Safety Biomarkers Will Continue to Dominate the Market in 2021
Figure 15 Diagnostics Segment Accounted for the Largest Market Share in 2016
Figure 16 Cancer Segment Accounted for the Largest Market Share in 2016
Figure 17 Asia to Account for the Highest CAGR During the Forecast Period
Figure 18 Asian Market Shows Lucrative Growth Opportunities
Figure 19 Market Drivers, Restraints, Opportunities, and Challenges
Figure 20 Increasing R&D Investments Boosting Growth in the Biomarkers Market
Figure 21 Increasing Number of New Cancer Cases Worldwide (2012 vs 2015 vs 2020)
Figure 22 Consumables Segment Accounted for the Largest Share of the Market in 2016
Figure 23 Safety Biomarkers Segment to Dominate the Market During the Forecast Period
Figure 24 Diagnostics Application Segment to Account for the Largest Share of the Biomarkers Market in 2016
Figure 25 Cancer to Form the Largest Segment in the Biomarkers Market in 2016
Figure 26 Biomarkers Market: Geographic Snapshot
Figure 27 Asia: an Attractive Destination for All Application Categories
Figure 28 North America: Market Snapshot
Figure 29 Asia: Market Snapshot
Figure 30 Product Launch, the Most Adopted Growth Strategy From 2014 to 2016
Figure 31 Geographic Revenue Mix of the Top 5 Market Players (2015)
Figure 32 Company Snapshot: Qiagen N.V. (2015)
Figure 33 Company Snapshot: Perkinelmer, Inc. (2015)
Figure 34 Company Snapshot: Merck Millipore (2015)
Figure 35 Company Snapshot: Bio-Rad Laboratories, Inc. (2015)
Figure 36 Company Snapshot: Enzo Biochem, Inc. (2016)
Figure 37 Company Snapshot: EKF Diagnostics Holdings, Inc. (2015)

The global biomarkers market is projected to reach USD 53.34 billion by 2021 from USD 27.95 billion in 2016, growing at a CAGR of 13.8% during the forecast period.

Growth in the market is mainly driven by factors such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, increasing number of CROs and low cost of clinical trials in developing countries, the high prevalence of cancer, and new initiatives for research. On the other hand, high capital investments and low cost-benefit ratio, poorly suited regulatory and reimbursement systems, and technical issues related to sample collection and storage are the major factors restraining the growth of this market.

On the basis of type, the market is segmented into safety, efficacy, and validation. The safety biomarkers have widespread applications in the drug discovery and development. Hence, this segment is estimated to account for the largest share in 2016.

The efficacy biomarkers segment is further segmented into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. The predictive segment is estimated to account for the largest share of the market in 2016. The large share and high growth of this segment can be attributed to the wide applications of predictive biomarkers in personalized medicine and companion diagnostics.

On the basis of disease indication, the market is categorized into cancer, cardiovascular disorders, neurological disorders, immunological disorders, and others (renal disorders, urinal diseases, diabetes, and tuberculosis). The cancer segment is estimated to account for the largest share of the market in 2016 due to the increasing prevalence of cancer worldwide.

The key players operating in the biomarker market are Qiagen (the Netherlands), PerkinElmer (US), and Merck Millipore (US). A majority of the leading players in the market focus on the strategy of product development. Players also focus on expanding their distribution networks by pursuing inorganic growth strategies such as agreements and collaborations. This enables them to cater to the increasing demand from consumers and provide easy-to-operate and efficient.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst